These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16828196)

  • 1. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
    Utkan G; Büyükçelik A; Yalçin B; Akbulut H; Demirkazik A; Dinçol D; Onur H; Gören D; Mousa U; Senler FC; Içli F
    Lung Cancer; 2006 Sep; 53(3):367-74. PubMed ID: 16828196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
    van Haarst JM; Baas P; Manegold Ch; Schouwink JH; Burgers JA; de Bruin HG; Mooi WJ; van Klaveren RJ; de Jonge MJ; van Meerbeeck JP
    Br J Cancer; 2002 Feb; 86(3):342-5. PubMed ID: 11875695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
    Kovac V; Zwitter M; Rajer M; Marin A; Debeljak A; Smrdel U; Vrankar M
    Anticancer Drugs; 2012 Feb; 23(2):230-8. PubMed ID: 22027538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
    Castagneto B; Zai S; Dongiovanni D; Muzio A; Bretti S; Numico G; Botta M; Sinaccio G
    Am J Clin Oncol; 2005 Jun; 28(3):223-6. PubMed ID: 15923792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
    Nowak AK; Byrne MJ; Williamson R; Ryan G; Segal A; Fielding D; Mitchell P; Musk AW; Robinson BW
    Br J Cancer; 2002 Aug; 87(5):491-6. PubMed ID: 12189542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
    Byrne MJ; Davidson JA; Musk AW; Dewar J; van Hazel G; Buck M; de Klerk NH; Robinson BW
    J Clin Oncol; 1999 Jan; 17(1):25-30. PubMed ID: 10458214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
    Kalmadi SR; Rankin C; Kraut MJ; Jacobs AD; Petrylak DP; Adelstein DJ; Keohan ML; Taub RN; Borden EC
    Lung Cancer; 2008 May; 60(2):259-63. PubMed ID: 18006112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
    Pinto C; Marino A; De Pangher Manzini V; Benedetti G; Galetta D; Mazzanti P; Del Conte G; dell'Amore D; Piana E; Giaquinta S; Lopez M; Martoni A
    Lung Cancer; 2006 May; 52(2):199-206. PubMed ID: 16542747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
    Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Ceresoli GL; Garassino I; De Vincenzo F; Cavina R; Campagnoli E; Cappuzzo F; Salamina S; Soto Parra HJ; Santoro A
    Cancer; 2008 Apr; 112(7):1555-61. PubMed ID: 18286536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
    Favaretto AG; Aversa SM; Paccagnella A; Manzini Vde P; Palmisano V; Oniga F; Stefani M; Rea F; Bortolotti L; Loreggian L; Monfardini S
    Cancer; 2003 Jun; 97(11):2791-7. PubMed ID: 12767092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
    Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
    Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
    Arrieta O; López-Macías D; Mendoza-García VO; Bacon-Fonseca L; Muñoz-Montaño W; Macedo-Pérez EO; Muñiz-Hernández S; Blake-Cerda M; Corona-Cruz JF
    Cancer Chemother Pharmacol; 2014 May; 73(5):975-82. PubMed ID: 24687408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
    Pasello G; Nicotra S; Marulli G; Rea F; Bonanno L; Carli P; Magro C; Jirillo A; Favaretto A
    Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    Simon GR; Verschraegen CF; Jänne PA; Langer CJ; Dowlati A; Gadgeel SM; Kelly K; Kalemkerian GP; Traynor AM; Peng G; Gill J; Obasaju CK; Kindler HL
    J Clin Oncol; 2008 Jul; 26(21):3567-72. PubMed ID: 18640937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.
    Portalone L; Antilli A; Nunziati F; Crispino C; de Marinis F; Friggeri L; Lombardi A; Lorusso V; Pronzato P; Sambiasi D; Signora M;
    Tumori; 2005; 91(1):15-8. PubMed ID: 15849999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
    Ralli M; Tourkantonis I; Makrilia N; Gkini E; Kotteas E; Gkiozos I; Katirtzoglou N; Syrigos K
    Anticancer Res; 2009 Aug; 29(8):3441-4. PubMed ID: 19661370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
    Tas F; Guney N; Derin D; Camlica H; Aydiner A; Topuz E
    Invest New Drugs; 2008 Aug; 26(4):363-8. PubMed ID: 18165864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
    Okuno SH; Delaune R; Sloan JA; Foster NR; Maurer MJ; Aubry MC; Rowland KM; Soori GS; Nikcevich DA; Kardinal CG; Northfelt DW; Adjei AA;
    Cancer; 2008 Apr; 112(8):1772-9. PubMed ID: 18224661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.